AbbVie’s decision to pay a $1.64 billion merger breakup fee to Dublin-based Shire PLC rather than face the sudden tax disadvantages of a corporate inversion was a normal risk assumed by a company’s board, the Delaware Court of Chancery has ruled in denying stockholders access to AbbVie’s records on the deal.
AbbVie was mulling a merger with Shire PLC in 2014 in an effort to switch its country of citizenship from the United States to a country with a tax structure the pharmaceutical company viewed more favorably. But when the U.S. Department of Treasury took a decidedly less favorable view of corporate inversions through its regulatory implementation, the tax advantages of the AbbVie-Shire merger disappeared.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]